News - Biotechnology, Licensing, GlaxoSmithKline

Filter

Epizyme earns $4 million milestone under GSK collaboration

22-04-2014

US clinical-stage biopharma firm Epizyme announced the achievement of the lead candidate milestone for…

BiotechnologyEpizymeFinancialGlaxoSmithKlineLicensingOncology

Amgen and GSK end marketing agreement for osteoporosis drug Prolia

Amgen and GSK end marketing agreement for osteoporosis drug Prolia

04-04-2014

World leading independent biotech firm Amgen revealed in a Securities and Exchange Commission filing…

AmgenAnti-Arthritics/RheumaticsBiotechnologyGlaxoSmithKlineLicensingProliaXgeva

GlaxoSmithKline returns Duchenne drug rights to Prosensa

GlaxoSmithKline returns Duchenne drug rights to Prosensa

13-01-2014

UK pharma giant GlaxoSmithKline says that its partner, Dutch biotech firm Prosensa has regained all rights…

BiotechnologydrisapersenGlaxoSmithKlineLicensingProsensaRare diseases

Big news day for Amicus, with change in GSK deal, an acquisition and restructuring

Big news day for Amicus, with change in GSK deal, an acquisition and restructuring

22-11-2013

US biotech firm Amicus Therapeutics saw its shares fall 4.2% to $2.03 by mid-morning trading on Thursday,…

Amicus TherapeuticsBiotechnologyCallidus BiopharmaFinancialGlaxoSmithKlineLicensingManagementMergers & AcquisitionsmigalastatRare diseases

Isis earns milestone payments from GlaxoSmithKline

Isis earns milestone payments from GlaxoSmithKline

07-10-2013

US biotech firm Isis Pharmaceuticals says that UK pharma giant GlaxoSmithKline has added a development…

BiotechnologyFinancialGlaxoSmithKlineIsis PharmaceuticalsLicensingPharmaceuticalRare diseases

Immunocore in multi-million deal with GlaxoSmithKline on ImmTACs

09-07-2013

Oxford, UK-based biotech firm Immunocore, focused on developing novel biological drugs called ImmTACs…

Anti-viralsBiotechnologyGlaxoSmithKlineImmunocoreLicensingOncologyPharmaceuticalResearch

Elan pays $1 billion for a 21% share of Theravance royalties on four respiratory programs

13-05-2013

US biotech firm Theravance (Nasdaq: THRX) has entered into a royalty participation agreement wherein…

Anoro ElliptaBiotechnologyBreo ElliptaElanFinancialGlaxoSmithKlineLicensingPharmaceuticalRespiratory and PulmonaryTheravance

GSK returns IPX066 rights to Impax; Merck & Co and Pfizer link up on diabetes drug

30-04-2013

US biotech firm Impax Laboratories (Nasdaq: IPXL) saw its shares fall 2% to $17.32 in premarket trading,…

BiotechnologyDiabetesertugliflozinGlaxoSmithKlineImpax LaboratoriesIPX066LicensingMerck & CoNeurologicalPfizerPharmaceuticalResearch

Amgen in $180 mill deal with BIND; Priaxon accord with GlaxoSmithKline

09-01-2013

BIND Biosciences, a US clinical stage investor backed company, and Amgen (Nasdaq: AMNG), the world's…

AmgenBIND BiosciencesBiotechnologyGlaxoSmithKlineLicensingOncologyPharmaceuticalPriaxon

NeRRe Therapeutics created to develop NRAs from GSK; GlycoVaxyn deal with GSK

20-12-2012

NeRRe Therapeutics was launched in the UK yesterday to develop a portfolio of clinical and pre-clinical…

Antibiotics and Infectious diseasesBiotechnologyFinancialGlaxoSmithKlineGlycoVaxynLicensingNeRReTherapeuticsNeurologicalNovo NordiskPharmaceuticalResearchVaccines

Isis Pharma/GlaxoSmithKline's ISIS-TTR Rx gains US fast-track designation

14-12-2012

In what has been a busy newsflow few days for USA-based Isis Pharmaceutical (Nasdaq: ISIS), the company…

BiotechnologyGlaxoSmithKlineIsis PharmaceuticalsISIS-TTR.RXLicensingNorth AmericaPharmaceuticalRare diseasesRegulation

News briefs: Japan clears filgrastim biosimilar; GSK to up stake in Nigerian and Indian firms; UCB deals

26-11-2012

Mid-sized Japanese drugmaker Mochida Pharmaceutical (TYO: 4534) says that it has received marketing…

Asia-PacificBiotechnologyExemed PharmaceuticalsFilgrastimFuji PharmaGlaxoSmithKlineLicensingMergers & AcquisitionsMochida PharmaceuticalNeupogenNewBridge PharmaceuticalsPharmaceuticalProductionRegulationRest of the WorldUCB

GlaxoSmithKline amends accord with Isis Pharma; gets FDA panel backing for raxibacumab

06-11-2012

USA-based Isis Pharmaceuticals (Nasdaq: ISIS) says it has agreed to amend the clinical development plan…

Antibiotics and Infectious diseasesBiotechnologyFinancialGlaxoSmithKlineIsis PharmaceuticalsISIS-TTR.RXLicensingNorth AmericaPharmaceuticalRare diseasesraxibacumabRegulationResearch

Biogen Idec sells Benlysta royalty rights to DRI for initial $18.3 million

11-09-2012

US biotech firm Biogen Idec (Nasdaq: BIIB) has sold to a Canada-based DRI Capital managed fund its royalty…

BenlystaBiogen IdecBiotechnologyFinancialGlaxoSmithKlineHuman Genome SciencesLicensingPharmaceuticalRare diseases

Pharma partnering dollars continue to decline, Burrill & Co reports

06-08-2012

The recent $3.4 billion partnering agreement announced in July between US pharma company Bristol-Myers…

AmylinAstraZenecaBiotechnologyBristol-Myers SquibbFinancialGlaxoSmithKlineHuman Genome SciencesLicensingMarkets & Marketing

Silencing investor concerns? Alnylam achieves RNAi milestone

02-08-2012

US RNAi therapeutics specialties Alnylam Pharmaceuticals (Nasdaq: ALNY) has received a $3.2 million milestone…

Alnylam PharmaceuticalsAnti-viralsBiotechnologyFinancialGlaxoSmithKlineLicensingProductionVaccines

GlaxoSmithKline files for new eltrombopag indications in EU and USA; gains rights to derma products

31-05-2012

UK pharma giant GlaxoSmithKline (LSE: GSK) revealed yesterday that it has submitted regulatory applications…

Anti-viralsBiotechnologyDermatologicalseltrombopagEuropeGlaxoSmithKlineLicensingNorth AmericaPharmaceuticalPromactaRegulationRevoladeStiefelWelichem Biotech

GlaxoSmithKline links with Japan's Chiome on MAbs

10-04-2012

UK pharma giant GlaxoSmithKline group (LSE: GSK) and Tokyo, Japan-based biotech-venture company Chiome…

BiotechnologyChiome BioscienceGlaxoSmithKlineImmunologicalsLicensingOncologyPharmaceuticalResearch

Epistem in fibrosis research deal with GlaxoSmithKline

13-03-2012

UK biotech and personalized medicines company Epistem (LSE:EHP) has entered into a three year biomarker…

BiotechnologyEpistemGlaxoSmithKlineLicensingPharmaceuticalResearch

Agenus expands deal with GlaxoSmithKline; Nuron in-licenses vaccines

06-03-2012

US biotech firm Agenus (Nasdaq: AGEN) says it has amended the QS-21 license and manufacturing agreement…

AgenusAkshaya BioBiotechnologyGlaxoSmithKlineLicensingNuron BiotechPharmaceuticalVaccines

GSK exercises option for Galapagos drug candidates

21-02-2012

Belgium-based Galapagos NV (Euronext: GLPG) says that its partner, UK pharma giant GlaxoSmithKline (LSE:…

Anti-Arthritics/RheumaticsBiotechnologyGalapagosGlaxoSmithKlineInflammatory diseasesLicensingPharmaceuticalResearch

Epizyme earns $4 million pre-clinical milestone from GSK under novel HMT therapeutics alliance

17-10-2011

Privately-held US biotech startup Epizyme says it has achieved a pre-clinical milestones in its alliance…

BiotechnologyEpizymeFinancialGlaxoSmithKlineLicensingOncologyPharmaceutical

Prosensa to get milestone payments from GSK under Duchenne collaboration

16-09-2011

Dutch biotech company Prosensa, focusing on rare diseases with an unmet medical need, has agreed with…

BiotechnologyFinancialGlaxoSmithKlineLicensingPharmaceuticalProsensaRare diseasesResearch

Back to top